Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

183
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
183
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

692
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
692
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

270
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270
Association Areas of the Cortex01:21

Association Areas of the Cortex

6.4K
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
6.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

732
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
732
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

396
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
396

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive, Motor and Oculomotor Contributions to the Trail Making Test in Progressive Supranuclear Palsy.

Movement disorders clinical practice·2026
Same author

A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.

Nature medicine·2026
Same author

The study of epigenetic clocks in former professional contact sports athletes with repetitive head impacts.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.

Nature genetics·2026
Same author

A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.

Nature genetics·2026
Same author

Cardiovascular risk factors and vascular neuropathological findings in primary age-related tauopathy versus Alzheimer's disease.

GeroScience·2026
Same journal

Practice Patterns and Care Gaps in Lennox Gastaut Syndrome: A call for Action.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Isolated Achiasma Discovered at Age 86: A Rare Cause of see-saw nystagmus and bitemporal hemianopia.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Post-Stroke Parakinesia Brachialis Oscitans: Clinical Insights from a Case Series.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

A Neuronal Perspective.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Diagnostic efficacy, costs, and safety of portable ultra-low field MRI in brain imaging: a systematic review.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same journal

Chronology of Non-Motor Symptoms in 100 Patients with Advanced PD of 10 Years' Duration: Pre- versus Post-Motor Period.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
See all related articles

Related Experiment Video

Updated: Sep 21, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.6K

Recent Advances in Frontotemporal Dementia.

Maria Carmela Tartaglia1, Ian R A Mackenzie2

  • 1Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|May 31, 2022
PubMed
Summary
This summary is machine-generated.

Frontotemporal dementia (FTD) is a neurodegenerative disorder with no cure. Recent molecular discoveries offer hope for developing new biomarkers and targeted treatments for this condition.

Keywords:
Frontotemporal dementiaFrontotemporal lobar degenerationPrimary progressive aphasia

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

375
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.2K

Related Experiment Videos

Last Updated: Sep 21, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

17.6K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

375
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.2K

Area of Science:

  • Neurology
  • Neuroscience
  • Genetics

Background:

  • Frontotemporal dementia (FTD) is a significant neurodegenerative disease with early onset and high heritability.
  • Despite its impact, effective treatments for FTD are lacking, and diagnosis is challenging due to clinical heterogeneity.

Purpose of the Study:

  • To summarize revised clinical criteria for FTD.
  • To highlight diagnostic challenges and recent molecular discoveries.
  • To focus on promising developments in FTD biomarkers and clinical trials.

Main Methods:

  • Review of recently revised clinical criteria for FTD.
  • Summary of current understanding of FTD molecular basis.
  • Overview of emerging biomarkers and ongoing clinical trials for FTD.

Main Results:

  • Revised clinical criteria for FTD diagnosis have been established.
  • Advances in understanding FTD's molecular underpinnings are paving the way for new therapies.
  • Promising biomarkers and clinical trials are under development.

Conclusions:

  • Despite diagnostic challenges, recent molecular insights into FTD are crucial.
  • The development of novel biomarkers and targeted therapies holds promise for future FTD treatment.
  • Continued research is essential for improving FTD diagnosis and patient outcomes.